Compare SKWD & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKWD | TXG |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2023 | 2019 |
| Metric | SKWD | TXG |
|---|---|---|
| Price | $51.16 | $16.40 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 13 |
| Target Price | ★ $65.30 | $15.42 |
| AVG Volume (30 Days) | 322.9K | ★ 1.9M |
| Earning Date | 10-29-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.25 | N/A |
| EPS | ★ 3.37 | N/A |
| Revenue | ★ $1,335,358,000.00 | $641,814,000.00 |
| Revenue This Year | $24.24 | $4.50 |
| Revenue Next Year | $30.16 | N/A |
| P/E Ratio | $15.34 | ★ N/A |
| Revenue Growth | ★ 22.27 | 1.92 |
| 52 Week Low | $41.28 | $6.78 |
| 52 Week High | $65.05 | $20.34 |
| Indicator | SKWD | TXG |
|---|---|---|
| Relative Strength Index (RSI) | 58.74 | 49.44 |
| Support Level | $51.50 | $15.91 |
| Resistance Level | $52.29 | $16.86 |
| Average True Range (ATR) | 1.29 | 0.71 |
| MACD | 0.15 | -0.10 |
| Stochastic Oscillator | 67.71 | 56.57 |
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).